US EditionNovo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control - Novo Nordisk (NYSE:NVO)
CagriSema reduced HbA1c by 1.91%-points and body weight by 14.2% over 68 weeks, outperforming semaglutide with a well-tolerated safety profile, Novo Nordisk reported.
- On Monday, Novo Nordisk shared headline REIMAGINE 2 results showing once-weekly CagriSema outperformed semaglutide across tested doses with greater HbA1c and weight reductions.
- The trial randomized 2,728 people with type 2 diabetes inadequately controlled on metformin ± SGLT2 inhibitor and compared once-weekly CagriSema to semaglutide, cagrilintide, and placebo.
- Detailed outcomes indicate from a mean baseline HbA1c of 8.2%, CagriSema 2.4 mg/2.4 mg achieved a 1.91% reduction versus 1.76% with semaglutide, and from a mean baseline body weight of 101 kg produced 14.2% weight loss versus 10.2%, with 43% reaching ≥15% and 24% reaching ≥20%.
- Safety data showed CagriSema appeared safe and well tolerated, with mainly mild-to-moderate gastrointestinal adverse events that diminished over time, and Lange said he was 'very pleased.'
- Novo Nordisk has already filed CagriSema for weight-loss in December 2025 after REDEFINE 1 and 2 showed 40% achieved 25% weight loss; analysts project peak sales of $7 billion or more against Eli Lilly's tirzepatide.
12 Articles
12 Articles
The Danish medicine New Nordisk, responsible for Ozempic and Wegovy medications, published, this week, data from a Phase 3, clinical trial, with the new CagriSema pen. The results showed that the injection led to a weight loss higher than that observed with Wegovy, the main drug of the company to treat obesity. Benefits of nodes: How much should you eat per day to benefit from the benefits? Not all days, not even once a week: How often should yo…
MedPage Today
Anti-Aging, Acupuncture and Health NewsGLP-1 Pill Cut Heart Failure Events in Some Diabetes Patients
(MedPage Today) -- Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, according to findings...
Novo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control - Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) on Monday shared headline results from the REIMAGINE 2 phase 3 trial from the global REIMAGINE clinical trial program. CagriSema for weight management was submitted to the U.S. Food and Drug Administration (FDA) in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials. Trial Data REIMAGINE 2 was a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination…
Semaglutide Pill Shows Heart Benefits in One Key Group, Study Finds
Taking oral semaglutide may reduce heart-related hospitalizations and deaths among those with a history of heart failure and type 2 diabetes, a new analysis suggests. Data from a trial funded by Novo Nordisk – which produces the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for weight loss (under the brand name Wegovy) and diabetes (Ozempic) – was reanalyzed by an international team of researchers. The double-blind study involved …
Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial
While Novo Nordisk's CagriSema drug also previously succeeded in two obesity studies, it fell short of expectations at the time.The post Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
